Hugel said on the 16th that it will tour major Chinese cities with strong demand for medical aesthetics to strengthen academic exchanges with local medical staff.
Starting this year in Beijing, the company plans to hold regional symposiums in a total of six cities, including Shanghai, Guangzhou, Hangzhou, Chengdu and Wuhan. It is part of efforts to raise awareness and trust in its flagship product, the botulinum toxin "Letybo."
According to the company, it held the "Letybo regional symposium and hands-on training" in Beijing on the 15th. The event featured in-depth discussions on a range of combined treatment cases and effects using Letybo, as well as future development directions.
The event invited Kim Jeong-hwan, chief director of Doctor Evers Myeong-dong in Korea, as the lead speaker, and about 30 local Chinese medical professionals attended. Wang Keming, chief physician at the Plastic Surgery Hospital of the Chinese Academy of Medical Sciences, and Qi Min, chief technology director of Huierhe Group, joined for joint lectures, on-site training and clinical case discussions.
Jee Seung-uk, a vice president at Hugel, said, "Based on academic events connecting China's major medical aesthetic hub cities, we will build a medical aesthetic exchange network that spans all of China," adding, "Through this, we will drive practical exchanges with local medical staff and solidify Hugel's brand presence and credibility."